Biolab & Co. is a Brazilian healthcare group that brings together pharmaceutical, generic medicine, and animal health businesses. Guided by the belief that science and care go hand in hand, the company focuses on promoting health and quality of life through technology, research, and responsible practices.

Its human health portfolio spans cardiology, vascular health, dermatology, gastroenterology, mobility, pediatrics, urology, women’s health, mental health, general and hospital care, vitamins, and supplements. Biolab also offers branded generics and products for animal health, including Avert® and Pet Nutrition® lines with formulas developed for pets’ general health. Research, development, and innovation are central to its work, supported by clinical studies, research and development centers, and collaborations with universities and startups.

The group also pursues business development and licensing opportunities, and has expanded its international presence through the acquisition of Canadian company Exzell Pharma. Biolab & Co. highlights environmental, social, and governance commitments, alongside initiatives for patients, healthcare professionals, pharmacists, and animal care